HA/HSA co-modified erlotinib–albumin nanoparticles for lung cancer treatment
Yuzhou Shen, Wentao Li Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, China Background: Aim of this study was to prepare the hyaluronic acid and human serum albumin modified erlotinib nanoparticles (ERT-HSA-HA NPs) delivery system by a prec...
Main Authors: | Shen Y, Li W |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2018-07-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/hahsa-co-modified-erlotinib-albumin-nanoparticles-for-lung-cancer-trea-peer-reviewed-article-DDDT |
Similar Items
-
Influence of Rutin, Sinapic Acid, and Naringenin on Binding of Tyrosine Kinase Inhibitor Erlotinib to Bovine Serum Albumin Using Analytical Techniques Along with Computational Approach
by: Tanveer A. Wani, et al.
Published: (2022-03-01) -
Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells
by: Ana Santos-Rebelo, et al.
Published: (2019-11-01) -
TAT-modified serum albumin nanoparticles for sustained-release of tetramethylpyrazine and improved targeting to spinal cord injury
by: Yan Lin, et al.
Published: (2021-01-01) -
Docetaxel-loaded human serum albumin (HSA) nanoparticles: synthesis, characterization, and evaluation
by: Na Qu, et al.
Published: (2019-01-01) -
Interaction Characterization of a Tyrosine Kinase Inhibitor Erlotinib with a Model Transport Protein in the Presence of Quercetin: A Drug–Protein and Drug–Drug Interaction Investigation Using Multi-Spectroscopic and Computational Approaches
by: Tanveer A. Wani, et al.
Published: (2022-02-01)